Given the role of PI3K and mTOR in the response of prostate cancer cells to radiation and hypoxia, preclinical studies investigated whether PI3K/AKT/mTOR inhibitors radiosensitized prostate cancer cells of different PTEN status. The gene discussed is AKT1; the disease is Familial prostate cancer.